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Abstract | Healthy individuals can harbour microscopic tumours and dysplastic foci in different organs in 
an undetectable and asymptomatic state for many years. These lesions do not progress in the absence of 
angiogenesis or inflammation. Targeting both processes before clinical manifestation can prevent tumour 
growth and progression. Angioprevention is a chemoprevention approach that interrupts the formation of 
new blood vessels when tumour cell foci are in an indolent state. Many efficacious chemopreventive drugs 
function by preventing angiogenesis in the tumour microenvironment. Blocking the vascularization of incipient 
tumours should maintain a dormancy state such that neoplasia or cancer exist without disease. The current 
limitations of antiangiogenic cancer therapy may well be related to the use of antiangiogenic agents too late in 
the disease course. In this Review, we suggest mechanisms and strategies for using antiangiogenesis agents 
in a safe, preventive clinical angioprevention setting, proposing different levels of clinical angioprevention 
according to risk, and indicate potential drugs to be employed at these levels. Finally, angioprevention may go 
well beyond cancer in the prevention of a range of chronic disorders where angiogenesis is crucial, including 
different forms of inflammatory or autoimmune diseases, ocular disorders, and neurodegeneration.
Albini, A. et al. Nat. Rev. Clin. Oncol. advance online publication 31 July 2012; doi:10.1038/nrclinonc.2012.120
Introduction
Cancer has been identified by the United Nations as 
a non-communicable disease posing a global health 
threat with considerable economic consequences.1,2 The 
cost of cancer care in the USA alone is projected to rise 
from US$125 billion in 2010 to US$207 billion by 2020.2 
Although great strides have been made in reducing 
mortality from cardiovascular disease and other non- 
communicable diseases through preventive efforts, cancer 
is still usually treated at advanced, often metastatic, disease 
stages.3 Screening methods have improved prognosis for 
some cancers;4 however, early detection is not yet possi-
ble for most malignancies, and the value of screening has 
been challenged for some tumours.5 Targeted therapies are 
emerging as useful therapies, but treating all patients with 
these costly agents is not economically sustainable.6,7 As 
the world population exceeds 7 billion, cancer prevention 
clearly becomes an urgent goal to pursue.
Many cancers can be prevented by lifestyle changes, 
such as avoiding tobacco use, excessive UV exposure, 
infectious agents, poor dietary habits and obesity.8 
Behavioural studies suggest that promotion of healthy 
dietary habits and exercise is only moderately success-
ful.9 Thus, cancer prevention remains a difficult task. 
Preclinical evidence suggests that cancer prevention is 
feasible, but for the population at large the question is how.
It is estimated that half of men and a third of women will 
be diagnosed with a cancer in their lifetime.10 The cancer 
diagnosis usually comes many years after the transform-
ing events that spawned the cancer. Chemoprevention, the 
pharmacological prevention of cancer, was proposed over 
three decades ago,11 but little has been invested to advance 
this life-saving approach, which should be inexpensive, 
non-toxic, and suitable for chronic administration. In this 
Review, we suggest a new consideration: limiting chemo-
prevention to tumour cells may be too specific. To be 
effective, cancer prevention should ideally impact on the 
organ microenvironment, boosting physiological defences 
against tumour development.12
Angiogenesis and angioprevention
Angiogenesis and inflammation are two host-dependent 
and interdependent hallmarks of cancer13 that have an 
early permissive role in tumorigenesis (Figure 1). Angio-
prevention is the term that we used 10 years ago when 
we proposed that angiogenesis inhibition was a common 
target of most cancer chemopreventive drugs.14 Although 
epithelial cells that harbour mutations retain distinct, 
organ-specific phenotypes, endothelial cells are gener-
ally untransformed and a common target across many 
cancers. Increasing evidence supports the angio prevention 
approach in preclinical models as well as in epidemiological 
and clinical intervention studies in humans. 
Judah Folkman first suggested that tumour dormancy 
could be maintained by preventing neovascularization 
of microscopic cancers.15 However, the clinical vali-
dation of antiangiogenic therapy was done in the context 
of metastatic disease. Although antiangiogenic therapy 
has improved the standard of care for some cancers, 
its overall clinical benefit is modest for most patients, 
mainly observed in the form of prolonged progression-
free survival.16,17 In the setting of heavy disease burden, 
most patients treated with antiangiogenic agents eventu-
ally experience disease progression due to evolution of 
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biological escape mechanisms by tumours.18 All these 
data raise the question: ‘are angiogenesis inhibitors being 
used in an optimal scenario?’
Angioprevention applies angiogenesis inhibition to 
predisposing conditions,14 such as chronic inflammation, 
hyperplastic or preneoplastic lesions, and occult tumours. 
Angiopreventive drugs are chemopreventive compounds 
that counteract angiogenesis and/or the underlying 
inflammation. The goal is to influence the tumour micro-
environment so that host defence systems are fortified 
to more durably suppress the development of clinically 
detectable tumours. Microscopic foci of transformed 
cells are very common in healthy individuals. Autopsy 
studies have shown that approximately 40% of women 
between 40 and 49 years old have occult breast cancers.19 
Similarly, in situ prostate cancer has been detected post-
mortem in 24% of men aged 60–70 years.20 Microscopic 
thyroid cancers are estimated to be present in 98% of 
indivi duals by the age of 70.21,22 Yet, these cancers are 
diagnosed in only 2%, 8%, and <0.5%, respectively, in 
these age groups. The body’s intrinsic ability to prevent 
tumour angiogenesis is one mechanism by which cancers 
are maintained in a prolonged dormant state.23 Although 
it is not known which individuals with occult cancers will 
go on to develop clinical disease, angioprevention has the 
potential to avert this fate.
In the context of cancer, immune cells act as Janus-like 
components: on one side they can destroy cancer cells; 
on the other side they can promote tumour angiogenesis, 
growth and dissemination.24–26 The presence of immune 
cells within tumours has been suggested to contribute 
to the carcinogenic and metastatic processes,13,27 and to 
tumour angiogenesis;24–26 their polarization seems to deter-
mine clinical outcome. A typical example is macro phages: 
classically-activated M1 macro phages produce antiangio-
genic Th1 cytokines (such as interleukin [IL]-12); by con-
trast, tumour-associated macrophages, M2 macrophages, 
Tie2-expressing macro phages and myeloid-derived sup-
pressor cells produce Th2 cytokines, allow tissue recon-
struction, growth promotion and angio genesis.28,29 Similar 
groupings have been proposed for poly morphonuclear 
neutrophils (PMNs) as either antitumour ‘PMN1’ (or 
N1) or pro tumour ‘PMN2’ (or N2) subsets that have a 
direct role in tumour angiogenesis.26,30 Protumour and 
Key points
 ■ Angiogenesis and inflammation are host-dependent hallmarks of cancer that 
can be targeted using prevention approaches long before tumours initiate 
and progress
 ■ Several prescription and non-prescription drugs are already available for use in 
angioprevention, as well as a growing array of nutraceuticals
 ■ We propose four levels of angioprevention: I for the ‘healthy’ population; II for 
patients with increased risk of cancer; III for preneoplastic lesions; and IV for 
prevention of cancer recurrence
 ■ There are several successes in cancer prevention that demonstrate 
clinical feasibility and levels of intervention, from no to little to intense 
physician involvement
 ■ To avoid toxicity while maintaining efficacy, angioprevention needs to achieve a 
degree of angiogenesis control that is not excessively suppressive, such that 
healthy vascular function is maintained
proangiogenic polarization have been demonstrated for 
most tumour microenvironment immune cells including 
dendritic, mast, T and B cells.25,26,28,29,31 Blocking chronic 
inflam mation can prevent protumour polarization and 
contribute to angioprevention.
Mechanisms of angioprevention
Vascular cell migration and invasion
Inhibition of proteases involved in the degradation of the 
vascular basement membrane and extracellular matrix 
suppresses angiogenesis and metastasis.32 Abnormal 
matrix remodelling by unchecked protease activity 
opens the way to sprouting vessels, by breaking the extra-
cellular matrix and favouring detachment, attachment 
and spatial organization of endothelial cells. Targeting 
this remodelling is one mechanism of action attributed 
to the antiangiogenic activity of green tea33 through inhi-
bition of the matrix metallo proteinases (MMP)-2 and 
MMP-9. Inhibition of matrix remodelling can occur by 
direct binding as well as indirect mechanisms including 
downregulation of proteases and protease stimulators and 
upregulation of protease inhibitors.34,35 MMP inhibition 
has a role in the mechanism of action of numerous angio-
preventive agents.36,37 Flavonoids such as fisetin, apigenin, 
and luteolin specifically and dose-dependently anta-
gonize MMP-9 gene and protein expression in endothelial 
cells.38 Organosulfur compounds such as sulforaphane 
and phenethyl isothiocyanate are naturally present in 
dietary cruciferous vege tables, including broccoli and 
Brussels sprouts. One key target of phenethyl isothio-
cyanate is protein kinase C, which leads to downstream 
inhibition of MMP-2 and MMP-9.39 Eugenol (4-allyl-2- 
methoxyphenol), a component of basil, also inhibits angio-
genesis through modu lation of MMP-2 and MMP-9; in 
addition, eugenol acts through modulation of VEGF, its 
receptor VEGFR-1, tissue inhibitor of metalloproteinases 
(CSC-21K, also known as TIMP-2) and RECK.40 Other 
angiopreventive compounds, including hyperforin, cur-
cumin, resveratrol, and sili binin, affect metalloproteases 
and other matrix proteolytic enzymes, thereby impacting 
on the migration and invasion of endothelial cells.35,41,42
Endogenous angiogenesis inhibitors and hormones
Many endogenous angiogenesis inhibitors reside within 
the host microenvironment, including thrombospondin-1, 
platelet factor 4, angiostatin and other plasminogen 
fragments, endostatin, tumstatin, alphastatin, arresten, 
canstatin, pigment epithelium-derived factor (PEDF), 
TIMP-2, ADAM-TS 9 and tetrahydrocortisol as well 
as some chemokines.43 Induction of these inhibitors by 
drugs or diet can ‘boost’ innate vascular suppression and 
curb microscopic tumour growth (Figure 2).43
Interferons (IFN) have long been known to inhibit angio-
genesis.44 Imiquimod is a topical immunomodulatory 
drug that is approved by the FDA for the treatment of 
actinic keratosis to prevent its progression to skin cancer.45 
This agent acts through activation of Toll-like receptor 7 
(TLR7) and production of IFN-α, IFN-β, IFN-γ, IL-12 
and IL-18;46 repression of MMP activity, and inhibition 
of tumour angiogenesis.47
REVIEWS
© 2012 Macmillan Publishers Limited. All rights reserved
NATURE REVIEWS | CLINICAL ONCOLOGY  ADVANCE ONLINE PUBLICATION | 3
As a preventative agent in women who have had oestro-
gen receptor-positive breast cancer, treatment with tamox-
ifen reduces the incidence of secondary breast cancer by 
more than 40%.48 Tamoxifen has antitumour activity 
independent of its anti-oestrogen action that is associ-
ated with endostatin production.49 A clinical study of early 
stage breast cancer showed that tamoxifen (20 mg/day) 
significantly increased endostatin levels in breast tissue and 
abdominal subcutaneous fat by 33%, while simultaneously 
lowering VEGF and angiogenin levels.50
Endothelial cells are sensitive to the hormonal milieu, 
such as during the menstrual cycle, and hormonal 
mimetics and antagonists show antiangiogenic activi-
ties.51 A diet high in phytoestrogens, such as genistein 
and enterolactone, slows breast cancer progression in a 
fashion similar to tamoxifen,52 with inhibition of pro-
inflammatory cytokines IL-1α and IL-1β that promote 
angiogenesis. Indeed, the phytoestrogens enterolactone, 
quercetin and curcumin alter oestrogen-dependent 
transcription of genes in breast cancer cells.53
Inflammation and inflammatory angiogenesis
Chronic inflammation, which promotes angiogenesis and 
is linked to the development of 30% of all cancers,25 is a 
primary target for angioprevention.24,26 Chronic use of 
anti-inflammatory agents prevents a wide range of human 
tumours.54–56 The angiopreventive agent resveratrol 
reduced neutrophil infiltration in mesenteric lymph nodes 
and lamina propria in a colon cancer model.57 The signal 
transducer and activator of transcription (STAT) family 
member STAT3 is a central signalling hub for immune 
cells,58 and is often activated in cancer cells, leading 
to expression of VEGF, IL-10 and IL-6, which in turn 
upregulates STAT3 signalling in endothelial and immune 
cell subsets in the tumour microenvironment.58 Several 
angiopreventive phytochemicals—such as apigenin, 
luteolin, and myricetin—target the STAT3 pathway,59,60 as 
well as other key mediators of inflammation, including the 
NF-κB, PI3K, TNF-α, and HIF-1α pathways.41,61
Cyclooxygenase-2 (COX-2) is another proinflammatory 
molecule that is overexpressed in many cancers, inclu ding 
breast, colorectal, lung, and prostate and pre neoplastic 
lesions, such as ductal carcinoma in situ, cervical intra-
epithelial neoplasia, prostatic intraepithelial neoplasia, 
Barrett’s oesophagus, and actinic keratosis, but is not 
highly expressed in healthy tissues.62 COX-2 promotes 
carcinogenesis as well as angiogenesis through both 
prostaglandin-related and non-prostaglandin-related 
mechanisms.63 The angiogenic mechanisms include 
induction of MMP-2 and MMP-9, production of VEGF, 
bFGF, and PDGF, and enhancement of αvβ3-mediated 
angiogenesis.62 COX-2 inhibition interferes with these 
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Figure 1 | Timing of angioprevention. After a transformation event, most tumours remain clinically indolent for years if not 
decades. Only after the angiogenic switch, driven by increasing inflammation, and many subsequent cycles of replication 
will a tumour become clinically detectable. At this point, it will have extensively progressed, is likely to have disseminated 
tumour cells and may already be metastatic. Angioprevention, which includes anti-inflammatory antiangiogenic 
mechanisms, needs to be started when a tumour is a dormant or hyperplastic foci or even before this stage, and sustained 
to maintain the tumour in this state. The observation that angioprevention efficacy increases as a function of time of 
application with angioprevention drugs, such as aspirin, is not surprising when seen in this context. These concepts must 
also be kept in mind when developing clinical trials.
REVIEWS
© 2012 Macmillan Publishers Limited. All rights reserved
4 | ADVANCE ONLINE PUBLICATION www.nature.com/nrclinonc
events,63 thus aspirin and COX-2 inhibitors are bona fide 
angiopreventive agents. VEGF, MMPs and NF-κB are also 
targets of the β-adrenergic receptor blocker propranolol 
that has been shown to be anti angiogenic, and is clinically 
active in infantile hemangiomas.64
Apoptosis, autophagy, senescence and stem cells
The induction of autophagy or forcing activated endo-
thelial cells into a quiescent state is also an angio preventive 
mechanism.65 Among chemopreventive compounds, 
the phytochemicals sulforaphane66 and resveratrol67 
can activate pathways leading to autophagy. Microarray 
data suggest that some angioprevention agents, such 
as N-acetyl-cysteine and 9-cis-retinoic acid, induce a 
molecular profile in endothelial cells similar to that of 
in vitro senescence.65,68
Beyond microscopic tumours, cancer stem cells (also 
known as cancer initiating cells) reside in, and are depen-
dent on, the tumour microvasculature. Angiogenesis 
inhibitors have been shown to decrease putative cancer 
stem cell numbers,69 suggesting that angiopreventive 
treatments could not only halt tumour growth but might 
also restrict cancer stem cell expansion.69
Metabolism and caloric restriction
Reduction of caloric intake and energy restriction reduces 
cancer risk.70 Pharmacological metabolism regulators are 
under investigation for cancer prevention. Agents such 
as 2-deoxyglucose (2-DG), antidiabetic agents target-
ing glucose metabolism (metformin, rosiglitazone and 
pioglitazone), and histone deacetylase inhibitors, all 
exhibit antiangiogenic activity.71–73
The mTOR pathway controls protein metabolism in 
concert with AMPK and Akt; therefore, over-activation 
of mTOR can induce VEGF-mediated angiogenesis 
(Figure 3).74 The mTOR inhibitors, rapamycin, sirolimus, 
temsirolimus and everolimus (rapalogs) are in clinical use 
based on dual antiangiogenic and antitumour proper-
ties.75 Rapalogs are undergoing clinical assessment for the 
secondary chemoprevention of skin cancer and secon-
dary cancers in patients who are immunosuppressed 
following transplantation.76,77 Metformin, an AMPK 
stimulator, inhibits mTOR and demonstrates antiangio-
genic activity in vitro and in vivo.78–80 Among its unique 
mechanisms is the upregulation of PEDF, an endogenous 
angiogenesis inhibitor.81
Redox stress is another key component of oncogenic-
induced chronic inflammation.13,25–27 Oxygen radicals can 
activate endothelial cells and influence cytokine release 
and vascular permeability.82 Antioxidants are widely pro-
posed for cancer prevention,83 and in endothelial cells an 
antioxidant response may restore redox homeostasis.84 
Many angiopreventive agents exert pleiotropic effects by 
inhibiting angiogenesis and inflammation mediated 
by redox-sensitive targets, such as NF-κB, Akt, mTOR 
(Figure 3).85,86 Because energy restriction and metabolic 
regulation have anti-inflammatory and angiosuppressive 
consequences,84,87,88 another benefit of angioprevention 
could be weight control (Box 1).
Angioprevention in the clinic
Clinically, angioprevention maintains transformed cells 
in a dormant state and keeps the microenvironment 
healthy so that transformation is hampered despite 
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Figure 2 | Angiogenesis is controlled by a balance of endogenous stimulators and inhibitors; in homeostasis, the sum of these 
effects is null. Stimuli, for example in wound healing, can tip the balance, at first in favour of angiogenesis, where many new 
vessels are formed, then towards antiangiogenesis, where excess vessels are pruned away. Some angioprevention approaches 
aim to boost endogenous inhibitor levels and/or lower stimulators. Cell polarization from protumour to antitumour phenotypes, 
and metabolic repression can also promote a microenvironment resistant to tumour vascularization and tumour expansion. 
Abbreviations: MMP, matrix metalloproteinase; ROS, reactive oxygen species; TIMP, tissue inhibitor of metalloproteinase.
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promoting stimuli. We propose four distinct levels of 
angioprevention (Figure 4).
Level I
This level is aimed at cancer prevention in the general 
healthy population at ‘lowest’ risk of developing cancer. In 
these low-risk individuals, intervention must be safe with 
few, if any, adverse effects. Possible interventions include 
dietary factors and scientifically supported dietary sup-
plements, caloric restriction, and aspirin, which is already 
used to prevent heart attack or stroke. Combinations of 
drugs or foods and nutritional supplements might have 
synergistic angiopreventive activity.89 For level I angio-
prevention, regulatory approval might be unnecessary 
as long as the interventions are safe and suitable for 
general application.
Level II
Level II angioprevention would be aimed at cancer pre-
vention in individuals at moderate-to-high cancer risk. 
These include healthy persons with genetic abnorma-
lities that are associated with a higher cancer risk (for 
example, BRCA1 and BRCA2 mutations, Li-Fraumeni 
syndrome and familial adenomatous polyposis), family 
history (any heritable cancer), occupational or lifestyle 
exposure (such as asbestos, toxins, tobacco and heavy 
alcohol consumption), immunosuppression (for example, 
transplan tation, or HIV) and/or metabolic syndromes 
(including diabetes). The higher cancer risk of indivi-
duals in this group justifies a higher risk tolerance for the 
angioprevention agents used than in level I.
Metformin is a well-tolerated drug suitable for level II 
angioprevention90 that is widely prescribed for type 2 
diabetes and is potentially also usable for level I angio-
prevention. Difluoromethylornithine (an inhibitor of 
polyamine synthesis) and sulindac,54 fenretinide and 
hormonal mimetics91 also fall into the level II angio-
prevention category. Selected phytocompounds (cur-
cumin, hyperforin, xanthohumol, and black raspberry 
extract) would also be appropriate,3,92 as well as synthetic 
triterpenoids, such as bardoxolone, which show potent 
antiangiogenic and anti-inflammatory activity.93–95
Level III
Individuals with pre-neoplastic lesions, such as skin 
actinic keratosis, oral leukoplakia, colon adenomas, 
cervical dysplasia, prostatic hypertrophy, and Barrett’s 
oesophagus would be eligible for level III angioprevention 
strategies. The risk for progression to frank carcinoma 
warrants a more-aggressive angiopreventive approach, 
with a greater risk-to-risk-tolerance ratio. A number of 
prescription drugs with angiogenesis inhibitory proper-
ties are available, such as imiquimod (for skin cancer), 
finasteride (for prostate cancer), and celecoxib (for colon 
cancer).96 For the latter, cardiac protective treatment 
is warranted.97
JAK
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Figure 3 | Selected key signalling pathways that are targets for angioprevention. STAT and NF-κB are closely associated 
with inflammation and angiogenesis. Agents blocking these pathways in endothelial cells could have angiopreventive 
activity. Angiopreventive compounds induce both free-radical scavenging or transient reactive oxygen species elevation, 
evoking antioxidant responses. The identification of molecular targets of angioprevention is important for drug design, for 
identifying predictive biomarkers, and as a rationale for combinatorial angioprevention. Abbreviations: MMP, matrix 
metalloproteinase; NSAID, non-steroidal anti-inflammatory drug; ROS, reactive oxygen species; TK, tyrosine kinase; 
STAT; signal transducer and transcription activator.
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Level IV
Level IV angioprevention aims to prevent disease recur-
rence in patients who have achieved cancer remission. 
An aggressive and sustained angiopreventive approach 
is necessary, since tumour cell dissemination is likely to 
exist.98 Prevention of pathological angiogenesis is of para-
mount importance for durable cures. Angiopreventive 
interventions must potently suppress the ‘soil’ (micro-
environment) as described by Steven Paget, so that 
the ‘seed’ (microscopic metastases) will not thrive.99,100 
Level IV therapies include antiangiogenic cancer agents, 
such as tyrosine kinase inhibitors (axitinib, pazopanib, 
sorafenib, and sunitinib), mTOR inhibitors (everolimus, 
and temsirolimus), and certain chemotherapeutic drugs 
administered at low dose in a ‘metronomic’ schedule.101 
Long-term administration of bevacizumab in the adjuvant 
setting is currently under clinical investigation.102,103
Regulatory issues, biomarker use
Regulatory approval of pharmaceuticals for chemo-
prevention has proved challenging. Both finasteride 
and dutasteride have been shown in large clinical trials 
to decrease risk of prostate cancer by 25–35% in treated 
healthy men, for example, but both were denied FDA 
approval for cancer prevention, because of uncertainty for 
applicability in the general population.104 The discovery 
of biomarkers for microscopic cancers may pave the way 
for monitoring the impact of angioprevention.105 Recent 
discoveries of proangiogenesis and antiangio genesis 
markers in the platelet proteome reflecting dormant 
cancers are now being translated to clinical studies.106–108 
Several microRNAs are highly expressed during angio-
genesis, particularly miR-126 that targets VEGF.109 
Effects of phytocompounds on vascular microRNAs are 
coming to light,110 including those with protective effects 
on endothelial cells.111 MicroRNAs might also be a key 
source of biomarkers useful in angioprevention and 
cancer prevention in general.112
Whether regulatory approval is required for clinical 
application of angioprevention remains an open ques-
tion. Dietary and over-the-counter drug angioprevention 
may not even require physician involvement at level I, 
while interventions from level II to level IV will need to be 
prescribed by a clinician.
Successful angioprevention
Clinical trials that assess antiangiogenesis and angiopre-
vention as an end point are underway (Table 1), increasing 
the urgency for identifying biomarkers for angio genesis.17 
However, a number of chemo preventive angiogenesis 
inhibitory agents have shown clinical efficacy. Here, 
we describe selected compounds that demonstrate 
angiopreventive benefits.
Fenretinide
Several retinoids inhibit angiogenesis, including fenreti-
nide.113 A multicentre, randomized chemoprevention 
trial evaluated the effect of fenretinide on the incidence 
of contra lateral tumours in women with stage I breast 
cancer, showing a 35% reduction in second breast cancer 
incidence in premenopausal women and significantly 
(95% CI 0.000–0.522; P = 0.0327) lower incidence of 
ovarian cancer in the fenretinide arm.114 An overall reduc-
tion by 17% (hazard ratio [HR] = 0.83; 95% CI 0.67–1.03) 
in second breast cancer incidence was observed with fen-
retinide after 14.6 years of follow up, along with a 38% 
(HR = 0.63; 95% CI 0.46–0.83) reduction in second breast 
cancer incidence in premenopausal women,114 reaching 
50% (P-age*treatment interaction = 0.023) in women aged 
40 years or younger. Fenretinide may be active in BRCA 
mutation carriers,113 and a randomized prevention trial is 
underway in women who are at high risk for breast and 
ovarian cancer.115
Metformin
Metformin, widely used as a treatment for type 2 diabetes,116 
is well tolerated and associated with limited, transient 
side effects. Retrospective population studies showed a 
21% reduced risk and improved survival for all cancers 
in patients with type 2 diabetes receiving metformin.117,118 
The results were significant even after adjusting for BMI, 
a cancer risk factor. Conversely, diabetics treated with 
non-metformin regimens had an increased (1.36–1.42 
fold) risk for cancer.117 Another study demonstrated 
that patients taking metformin experienced a 62% risk 
reduction for pancreatic cancer.119 Metformin upregu-
lates circu lating levels of the antiangiogenic extracellular 
matrix molecule thrombospondin-1 (TSP-1) in insulin-
resistant obese women, likely one protective mechanism 
of action.87
Aspirin and NSAIDs
Observational studies of long-term use of aspirin or 
NSAIDs revealed a reduced risk of colon, breast, pros-
tate and lung cancer.56 Colon cancer and colon polyp 
Box 1 | Angioprevention—not only in cancer
Pathological angiogenesis is a common denominator of many disorders,96 
suggesting that clinical angioprevention may provide benefits in a wide range 
of conditions beyond cancer. In contrast to cancer, other pathologies often 
show more dependence on specific angiogenic pathways, further enhancing 
targeted drug action; the success of angiogenesis inhibition in the treatment 
of ‘wet’ age-related macular degeneration (AMD) is an example.145 This can be 
extended into the angioprevention realm. Epidemiological evidence suggests 
long-term non-steroidal anti-inflammatory drug (NSAID) use is associated with 
reduced risk of Alzheimer’s disease, where pathological brain microvessels 
are characteristic.146,147 The AREDS (Age-related Eye Disease Study) formula 
supplementation148 might implicate angioprevention in the neovascular form of 
AMD. Pathological angiogenesis driven by hypoxia and inflammation leads to joint 
destruction in patients with rheumatoid arthritis,149,150 where angioprevention may 
avert its progression. Angioprevention could even be used to prevent the growing 
epidemic of obesity, since controlling angiogenesis regulates adipose mass.151–153 
Genetic polymorphisms of VEGF are associated with childhood obesity,154 
and human studies have correlated BMI with inflammatory biomarkers (CRP) and 
angiogenesis (VEGF).143 Green tea intake reduced visceral fat in adults by 6% 
over 12 weeks in a small, prospective, controlled trial;155 other compounds such 
as synthetic triterpenoids are showing promise.156 Finally, many angiopreventive 
compounds, including phytochemicals, are showing protective effects on the 
cardiovascular system, not only by inhibiting atherosclerosis through suppressing 
plaque neovascularisation, but also by preventing collateral damage during cancer 
chemotherapy, while often enhancing efficacy.42 Combinatorial angioprevention 
regimens are a highly promising but untapped frontier.
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formation have undergone extensive study, because they 
are frequent lesions, higher risk groups can be identi-
fied and treated, and regular colonoscopy can be used 
to establish an accurate end point for both colon polyps 
and cancer. Multiple studies have shown that aspirin and 
NSAIDs, in particular selective COX-2 inhibitors, reduce 
colonic adenoma formation.54,120 Three large trials have 
now shown that regular, long-term aspirin use does 
reduce cancer incidence. Two of these, studying aspirin 
for cardioprotection,55,121 showed that regular aspirin use, 
independent of dose, decreases incidence and morta-
lity of numerous cancers, with even greater reduction 
for a subset of cancers, including colorectal, lung, and 
brain cancer. Long-term usage (>5 years) was needed 
for these differences to become evident.55 A large trial 
in patients with Lynch syndrome at risk for colorectal 
cancer showed significant differences in colorectal cancer 
incidence for a subgroup of individuals using aspirin 
for at least 2 years.122 Aspirin has antiangiogenic activ-
ity that is mediated through both COX-dependent and 
independent mechanisms.123–125
Celecoxib, a selective COX-2 inhibitor and potent 
anti-inflammatory agent, suppresses angiogenesis and 
has been clinically validated as a prevention agent for 
both sporadic colon adenomas and familial adenomatous 
polyposis.126,127 To mitigate the cardiovascular toxicities 
of celecoxib, low circulating levels of C-reactive protein 
may identify patients for whom the risk–benefit ratio of 
celecoxib chemoprevention is favourable.128
A double-blind, controlled randomized trial of 240 indi-
viduals with actinic keratosis showed that treatment with 
celecoxib for 9 months had a 60% reduction in the mean 
number of basal-cell and squamous-cell skin cancers.129 A 
combination of sulindac and 2-difluoromethylornithine 
also demonstrated a remarkable reduction in colon 
adenoma formation.54
Polyphenols
Green tea consumption is associated with a decreased 
risk of colon, prostate, lung, oesophageal, and other 
cancers;3,41,130 catechins are usually considered to be 
the active agents. A double-blind, placebo-controlled 
study in men with high-grade prostatic intraepithelial 
neoplasia showed that consuming green tea catechins 
(600 mg/day, equivalent to 4–6 cups of tea/day) over 
1 year reduced progression to prostate cancer from 30% 
in the placebo group to 3% in the treatment arm.130,131 
A Japanese study in patients following removal of 
colon polyps demonstrated that consumption of poly-
phenols equivalent to 12 cups of tea/day reduced the risk 
of adenoma recurrence by 50%.132 Preventive effects of 
green tea on precancerous oral and cervical lesions have 
been documented.133,134 Extensive literature has associ-
ated green tea catechins with the inhibition of several 
pathways and molecules related to angio prevention. 
Polyphenon E, a catechin-rich extract from green tea 
leaves is being evaluated in multiple clinical trials of 
prostate, bladder, oesophageal, lung, head and neck 
cancers, as well as leukaemia, and is already commercially 
available as a topical ointment.135
Curcumin targets numerous angiogenesis mediators 
and inhibitors,86 with beneficial effects in wound healing, 
as well as antiangiogenic effects in cancer. Phase I–II 
clinical trials established that curcumin is well tolerated 
at doses up to 8 g/day without showing dose-limiting 
toxicity,136,137 and pharmacological manipulations are 
ongoing to increase bioavailability of the natural mol-
ecule. Consistent data suggest curcumin is a promising 
candidate for colorectal cancer prevention. Curcumin 
in combination with quercetin decreased aberrant crypt 
foci by 40% in a phase IIa trial,138 and also decreased the 
incidence of colon adenomas in patients with familial 
adenomatous polyposis.139
Preclinical evidence of resveratrol activity in colo-
rectal cancer prevention prompted phase I studies to 
assess the pharmacokinetics, pharmacodynamics and 
safety of the drug or more bioavailable derivatives in 
healthy volunteers or cancer patients.140,141 Remarkably, 
a randomized double-blind crossover study in healthy 
obese men showed that resveratrol (150 mg/day for 
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Figure 4 | Four levels of angioprevention. All humans are at risk for developing cancer. As risk level increases, there is greater 
tolerance of collateral effects to obtain more benefit. Low toxicity interventions can be continued throughout higher levels. 
Abbreviations: BPH, benign prostatic hyperplasia; mAb, monoclonal antibody; NSAID, non-steroidal anti-inflammatory drug.
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30 days) exerts caloric-restriction-like effects, improves 
lipid profiles and decreases inflammatory markers.142 
Considering that metabolic disorders are associated with 
pathological angiogenesis and chronic inflammation143 
and can be predisposing conditions for some cancers,70 
these results constitute an important premise for further 
clinical studies.
Conclusions
A decade after its initial proposal, angioprevention is 
becoming a clinical reality that further shifts how we 
approach oncological disease, and uses strategies suit-
able for healthy individuals as well as those at high risk 
for cancer. Compared with classic chemoprevention 
directed at cancer cells, the inhibition of angiogenesis 
Table 1 | Clinical trials of chemoprevention with antiangiogenic principles*
Compound Molecular target 
or mechanism
Condition (ClinicalTrials.gov identifier) Phase Study type 
or design
n
Metabolic regulators
Metformin VEGF, mTOR, AMPK, 
MMP-2, MMP-978–80,87,90,117
Barretts’s metaplasia (NCT01447927)
Colorectal adenoma or high BMI (NCT01312467)
Prostate cancer (NCT01433913)
II
II
II
I, R, DB
I, NR, OL
I, R, DB
86
39
50
Pioglitazone PPARγ agonist, bFGF, VEGF, 
IL-8, CXCL5, CXCL171
Lung cancer (NCT00780234) II I, R, DB 126
Anti-inflammatory agents
Aspirin and tea 
polyphenols
COX inhibitor, VEGF, 
COX-independent 
MOA120–124
Oesophageal squamous cell carcinoma 
(NCT01496521)
III I, R, DB 600
Aspirin and 
esomeprazole
COX inhibitor, VEGF, 
COX-independent 
MOA120–124
Barretts’s metaplasia (NCT00357682) III I, R, OL 2,513
Aspirin and 
eflornithine
COX inhibitor, VEGF, 
COX-independent 
MOA120–124
Familial adenomatous polyposis (NCT00983580) II I, R, DB 52
Sulindac‡ COX-2 inhibitor54,56,60 Oral premalignant lesions (NCT00299195) P I, R, DB 66
Sulindac and 
eflornithine
COX-2 inhibitor54,56,60 Colorectal premalignant or nonmalignant lesions 
(NCT00118365)
III I, R, DB 178
Celecoxib‡ COX-2 inhibitor54,56,126,127,129 Cervical intraepithelial neoplasia (NCT00081263) II I, R, DB 130
Phytochemicals and derivatives
Curcumin NF-κB, VEGF, mTOR, 
miR-213,53,86,110,138,139
Familial adenomatous polyposis (NCT00927485)
Colorectal cancer (NCT01333917)
–
I
I, R, DB
I, OL, SG, Ph
50
40
Polyphenon E MMPs, STAT3, 
VEGF3,34,35,41,130,131
Prostatic intraepithelial neoplasia (NCT00596011)
Ductal carcinoma in situ (NCT01060345)
Bronchial dysplasia (NCT00611650)
Cervical intraepithelial neoplasia (NCT00303823)
II
P
II
II
I, R, DB
I, NR, SG, OL
I, R, DB
I, R, DB
272
50
23
208
Resveratrol NF-κB, IGF axis, EGF, 
VEGF54,61,140–142
Healthy adult smokers (NCT01492114)
Impaired glucose tolerance (NCT01375959)
III
P
I, R, DB, CS
I, R, DB, CS
40
30
Genistein NF-κB, AP-1, uPA, FAK, 
VEGF, HIF-1α, PTEN42,52,84
Type II diabetes mellitus (NCT00951912)
High risk for breast cancer (NCT00290758)
–
IIb
I, R, DB
I, R, DB
180
126
Genistein and 
vitamin D
NF-κB, AP-1, uPA, FAK, 
VEGF, HIF-1α, PTEN42,52,84
Early stage prostate cancer (NCT01325311) II I, R, DB 50
Black raspberry COX-2, iNOS92 Head and neck cancer (NCT01469429) I–II I, R, OL 140
Sulforaphane HDAC, Nrf2, VEGF, HIF-1α, 
MMPs3,66,95
Prostate cancer (NCT01265953)
Prostate cancer (NCT00946309)
–
I–II
I, R, DB
I, R, DB
100
100
Other compounds
Propranolol VEGF, MMP-2, MMP-9, 
NF-κB64
Infantile haemangioma (NCT01074437) II I, R, DB 60
Imiquimod MMP-9, interferons46,47 Lentigo maligna (NCT01088737) II–III I, NR, SG, OL 60
Everolimus mTOR75 Skin cancer (NCT00799188) III I, R, OL 175
Fenretinide IGF-1/IGFBPs113,114 High risk for breast cancer (NCT01479192) III I, R, DB 764
Tamoxifen Oestrogen receptor, 
angiogenin, VEGF, 
endostatin49–52
Breast cancer (NCT01357772) III I, R, DB 1,400
*Selected active clinical trials with known status and prevention as primary purpose are shown. ‡This trial has treatment as primary purpose, but vascular 
correlates as outcome measurement. Abbreviations: COX, cyclooxygenase; CS, crossover; DB, double-blind; HDAC, histone deacetylase; I, interventional; 
IL, interleukin; iNOS, inducible nitric oxide synthase; MMP, matrix metalloproteinase; MOA, mechanism of action; NR, non-randomized; OL, open-label; P, pilot; 
Ph, pharmacodynamics end point; R, randomized; SG, single-group; STAT, signal transducer and activator of transcription; uPA, urokinase-type plasminogen activator.
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and inflammation boosts anticancer defence mecha-
nisms and provides protection against a broad spectrum 
of neoplasms.
We propose four levels of angioprevention: level I for 
the ‘healthy’ population; level II for those with conditions 
associated with a raised risk of cancer; level III for treat-
ment of preneoplastic lesions; and level IV for prevention 
of recurrence of overt cancer. Angioprevention at levels I 
and II must be fundamentally non-toxic. Angiogenesis is 
crucial for wound healing and reproductive function, so 
angioprevention must be titrated to suppress undesirable 
angiogenesis, but not subvert healthy endothelial main-
tenance or function. We compare this goal of physio-
logically compatible angioprevention to the ‘Goldilocks 
Zone’ concept used by cosmologists seeking planets where 
life forms may reside.144 The term originated from the 
fairy tale about a child seeking porridge that is neither too 
hot nor too cold, but is ‘just right’. Angioprevention needs 
to achieve a degree of angiogenesis control that is neither 
over exuberant nor dangerously suppressed, without 
interfering with the Goldilocks Zone of healthy vascular 
function. One point that can be made is that many effi-
cacious angioprevention drugs have multiple targets, yet 
do not completely inhibit any single pathway. This may 
lead to lower toxicity when compared with most potent 
single-target drugs. Several natural backbones of phyto-
chemicals, such as aspirin, have been modified and tested 
for anticancer or chemopreventive activity. Molecular 
homologues could be designed from a chemopreventive 
backbone to be more antiangiogenic and more suitable 
as angiopreventives. Synthetic chemistry and mo lecular 
tailoring may be used to design angiopreventive diet 
derivatives or pharmaceuticals.
Clinical trials are now underway to test the efficacy of 
angiopreventive molecules such as curcumin, artemi-
sinin, resveratrol, genistein, synthetic triterpenoids, and 
isothiocyanates in neurological, cardiovascular degener-
ative diseases, and cancer at levels III and IV as defined in 
this article. Given the global health priorities facing socie-
ties today, and with the cancer pandemic in our sights, 
angioprevention and its clinical development is a concept 
whose time has arrived.
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